APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neoantigen Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neoantigen Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174016270431 December 2025208 pages

Choose your research edition.

Industry ResearchNeoantigen Vaccine Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neoantigen Vaccine Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neoantigen Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neoantigen Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Neoantigen Vaccine Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neoantigen Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neoantigen Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neoantigen Vaccine market include Merck & Co Inc, Eli Lilly and Company, Pfizer, ZIOPHARM Oncology, Vaximm AG, Vaccibody AS, Roche Holding AG, OSE Immunotherapeutics and Novogene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neoantigen Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neoantigen Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neoantigen Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neoantigen Vaccine market.

Neoantigen Vaccine Segment by Company

Merck & Co Inc

Eli Lilly and Company

Pfizer

ZIOPHARM Oncology

Vaximm AG

Vaccibody AS

Roche Holding AG

OSE Immunotherapeutics

Novogene

Nouscom

Moderna

Medigene AG

ISA Pharmaceuticals

Gritstone Bio

Genocea Biosciences Inc

BrightPath Biotherapeutics

BioNTech

Avidea Technologies

Agenus Inc

Advaxis

Neoantigen Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Neoantigen Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Neoantigen Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neoantigen Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neoantigen Vaccine key companies, revenue, market share, and recent developments.

3. To split the Neoantigen Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neoantigen Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neoantigen Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Neoantigen Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neoantigen Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neoantigen Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neoantigen Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neoantigen Vaccine industry.

Chapter 3: Detailed analysis of Neoantigen Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neoantigen Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neoantigen Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neoantigen Vaccine Industry Trends Table 2. Neoantigen Vaccine Industry Drivers Table 3. Neoantigen Vaccine Industry Opportunities and Challenges Table 4. Neoantigen Vaccine Industry Restraints Table 5. Global Neoantigen Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neoantigen Vaccine Revenue Share by Company (2021-2026) Table 7. Global Neoantigen Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neoantigen Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Neoantigen Vaccine Company, Product Type & Application Table 10. Global Neoantigen Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neoantigen Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Personalized Vaccine Table 15. Significant Companies of Off-the shelf Vaccine Table 16. Global Neoantigen Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Neoantigen Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Neoantigen Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Neoantigen Vaccine Sales Value Share by Type (2021-2026) Table 20. Global Neoantigen Vaccine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Gastrointestinal Cancer Table 22. Significant Companies of Lung Cancer Table 23. Significant Companies of Melanoma Cancer Table 24. Significant Companies of Brain Cancer Table 25. Significant Companies of Others Table 26. Global Neoantigen Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neoantigen Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Neoantigen Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Neoantigen Vaccine Sales Value Share by Application (2021-2026) Table 30. Global Neoantigen Vaccine Sales Value Share by Application (2027-2032) Table 31. Global Neoantigen Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neoantigen Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Neoantigen Vaccine Sales Value Share by Region (2021-2026) Table 34. Global Neoantigen Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Neoantigen Vaccine Sales Value Share by Region (2027-2032) Table 36. Global Neoantigen Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neoantigen Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Neoantigen Vaccine Sales Value Market Share by Country (2021-2026) Table 39. Global Neoantigen Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Neoantigen Vaccine Sales Value Market Share by Country (2027-2032) Table 41. Merck & Co Inc Company Information Table 42. Merck & Co Inc Business Overview Table 43. Merck & Co Inc Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Merck & Co Inc Neoantigen Vaccine Product Portfolio Table 45. Merck & Co Inc Recent Development Table 46. Eli Lilly and Company Company Information Table 47. Eli Lilly and Company Business Overview Table 48. Eli Lilly and Company Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eli Lilly and Company Neoantigen Vaccine Product Portfolio Table 50. Eli Lilly and Company Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pfizer Neoantigen Vaccine Product Portfolio Table 55. Pfizer Recent Development Table 56. ZIOPHARM Oncology Company Information Table 57. ZIOPHARM Oncology Business Overview Table 58. ZIOPHARM Oncology Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio Table 60. ZIOPHARM Oncology Recent Development Table 61. Vaximm AG Company Information Table 62. Vaximm AG Business Overview Table 63. Vaximm AG Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Vaximm AG Neoantigen Vaccine Product Portfolio Table 65. Vaximm AG Recent Development Table 66. Vaccibody AS Company Information Table 67. Vaccibody AS Business Overview Table 68. Vaccibody AS Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Vaccibody AS Neoantigen Vaccine Product Portfolio Table 70. Vaccibody AS Recent Development Table 71. Roche Holding AG Company Information Table 72. Roche Holding AG Business Overview Table 73. Roche Holding AG Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Roche Holding AG Neoantigen Vaccine Product Portfolio Table 75. Roche Holding AG Recent Development Table 76. OSE Immunotherapeutics Company Information Table 77. OSE Immunotherapeutics Business Overview Table 78. OSE Immunotherapeutics Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio Table 80. OSE Immunotherapeutics Recent Development Table 81. Novogene Company Information Table 82. Novogene Business Overview Table 83. Novogene Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novogene Neoantigen Vaccine Product Portfolio Table 85. Novogene Recent Development Table 86. Nouscom Company Information Table 87. Nouscom Business Overview Table 88. Nouscom Neoantigen Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Nouscom Neoantigen Vaccine Product Portfolio Table 90. Nouscom Recent Development Table 91. Moderna Company Information Table 92. Moderna Business Overview Table 93. Moderna Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Moderna Neoantigen Vaccine Product Portfolio Table 95. Moderna Recent Development Table 96. Medigene AG Company Information Table 97. Medigene AG Business Overview Table 98. Medigene AG Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Medigene AG Neoantigen Vaccine Product Portfolio Table 100. Medigene AG Recent Development Table 101. ISA Pharmaceuticals Company Information Table 102. ISA Pharmaceuticals Business Overview Table 103. ISA Pharmaceuticals Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio Table 105. ISA Pharmaceuticals Recent Development Table 106. Gritstone Bio Company Information Table 107. Gritstone Bio Business Overview Table 108. Gritstone Bio Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Gritstone Bio Neoantigen Vaccine Product Portfolio Table 110. Gritstone Bio Recent Development Table 111. Genocea Biosciences Inc Company Information Table 112. Genocea Biosciences Inc Business Overview Table 113. Genocea Biosciences Inc Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio Table 115. Genocea Biosciences Inc Recent Development Table 116. BrightPath Biotherapeutics Company Information Table 117. BrightPath Biotherapeutics Business Overview Table 118. BrightPath Biotherapeutics Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio Table 120. BrightPath Biotherapeutics Recent Development Table 121. BioNTech Company Information Table 122. BioNTech Business Overview Table 123. BioNTech Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. BioNTech Neoantigen Vaccine Product Portfolio Table 125. BioNTech Recent Development Table 126. Avidea Technologies Company Information Table 127. Avidea Technologies Business Overview Table 128. Avidea Technologies Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Avidea Technologies Neoantigen Vaccine Product Portfolio Table 130. Avidea Technologies Recent Development Table 131. Agenus Inc Company Information Table 132. Agenus Inc Business Overview Table 133. Agenus Inc Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Agenus Inc Neoantigen Vaccine Product Portfolio Table 135. Agenus Inc Recent Development Table 136. Advaxis Company Information Table 137. Advaxis Business Overview Table 138. Advaxis Neoantigen Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Advaxis Neoantigen Vaccine Product Portfolio Table 140. Advaxis Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Neoantigen Vaccine Product Image Figure 2. Global Neoantigen Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Neoantigen Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Personalized Vaccine Image Figure 8. Off-the shelf Vaccine Image Figure 9. Global Neoantigen Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Neoantigen Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Neoantigen Vaccine Sales Value Share by Type (2021-2032) Figure 12. Gastrointestinal Cancer Image Figure 13. Lung Cancer Image Figure 14. Melanoma Cancer Image Figure 15. Brain Cancer Image Figure 16. Others Image Figure 17. Global Neoantigen Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neoantigen Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neoantigen Vaccine Sales Value Share by Application (2021-2032) Figure 20. Global Neoantigen Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Neoantigen Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Neoantigen Vaccine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Neoantigen Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Neoantigen Vaccine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Neoantigen Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Neoantigen Vaccine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Neoantigen Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Neoantigen Vaccine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Neoantigen Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Neoantigen Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Neoantigen Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Neoantigen Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Merck & Co Inc
  • Eli Lilly and Company
  • Pfizer
  • ZIOPHARM Oncology
  • Vaximm AG
  • Vaccibody AS
  • Roche Holding AG
  • OSE Immunotherapeutics
  • Novogene
  • Nouscom
  • Moderna
  • Medigene AG
  • ISA Pharmaceuticals
  • Gritstone Bio
  • Genocea Biosciences Inc
  • BrightPath Biotherapeutics
  • BioNTech
  • Avidea Technologies
  • Agenus Inc
  • Advaxis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neoantigen Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neoantigen Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neoantigen Vaccine Market Dynamics
  1. 2.1 Neoantigen Vaccine Industry Trends
  2. 2.2 Neoantigen Vaccine Industry Drivers
  3. 2.3 Neoantigen Vaccine Industry Opportunities and Challenges
  4. 2.4 Neoantigen Vaccine Industry Restraints
3 Neoantigen Vaccine Market by Company
  1. 3.1 Global Neoantigen Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Neoantigen Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Neoantigen Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Neoantigen Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Neoantigen Vaccine Company Product Type and Application
  6. 3.6 Global Neoantigen Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neoantigen Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neoantigen Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neoantigen Vaccine Market by Type
  1. 4.1 Neoantigen Vaccine Type Introduction
  2. 4.1.1 Personalized Vaccine
  3. 4.1.2 Off-the shelf Vaccine
  4. 4.2 Global Neoantigen Vaccine Sales Value by Type
  5. 4.2.1 Global Neoantigen Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neoantigen Vaccine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Neoantigen Vaccine Sales Value Share by Type (2021-2032)
5 Neoantigen Vaccine Market by Application
  1. 5.1 Neoantigen Vaccine Application Introduction
  2. 5.1.1 Gastrointestinal Cancer
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Melanoma Cancer
  5. 5.1.4 Brain Cancer
  6. 5.1.5 Others
  7. 5.2 Global Neoantigen Vaccine Sales Value by Application
  8. 5.2.1 Global Neoantigen Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Neoantigen Vaccine Sales Value by Application (2021-2032)
  10. 5.2.3 Global Neoantigen Vaccine Sales Value Share by Application (2021-2032)
6 Neoantigen Vaccine Regional Value Analysis
  1. 6.1 Global Neoantigen Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neoantigen Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neoantigen Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neoantigen Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neoantigen Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Neoantigen Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neoantigen Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Neoantigen Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neoantigen Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neoantigen Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neoantigen Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Neoantigen Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neoantigen Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neoantigen Vaccine Sales Value Share by Country, 2025 VS 2032
7 Neoantigen Vaccine Country-level Value Analysis
  1. 7.1 Global Neoantigen Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neoantigen Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neoantigen Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neoantigen Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neoantigen Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neoantigen Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neoantigen Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co Inc
  2. 8.1.1 Merck & Co Inc Company Information
  3. 8.1.2 Merck & Co Inc Business Overview
  4. 8.1.3 Merck & Co Inc Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co Inc Neoantigen Vaccine Product Portfolio
  6. 8.1.5 Merck & Co Inc Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Neoantigen Vaccine Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Neoantigen Vaccine Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 ZIOPHARM Oncology
  20. 8.4.1 ZIOPHARM Oncology Company Information
  21. 8.4.2 ZIOPHARM Oncology Business Overview
  22. 8.4.3 ZIOPHARM Oncology Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio
  24. 8.4.5 ZIOPHARM Oncology Recent Developments
  25. 8.5 Vaximm AG
  26. 8.5.1 Vaximm AG Company Information
  27. 8.5.2 Vaximm AG Business Overview
  28. 8.5.3 Vaximm AG Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vaximm AG Neoantigen Vaccine Product Portfolio
  30. 8.5.5 Vaximm AG Recent Developments
  31. 8.6 Vaccibody AS
  32. 8.6.1 Vaccibody AS Company Information
  33. 8.6.2 Vaccibody AS Business Overview
  34. 8.6.3 Vaccibody AS Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vaccibody AS Neoantigen Vaccine Product Portfolio
  36. 8.6.5 Vaccibody AS Recent Developments
  37. 8.7 Roche Holding AG
  38. 8.7.1 Roche Holding AG Company Information
  39. 8.7.2 Roche Holding AG Business Overview
  40. 8.7.3 Roche Holding AG Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Holding AG Neoantigen Vaccine Product Portfolio
  42. 8.7.5 Roche Holding AG Recent Developments
  43. 8.8 OSE Immunotherapeutics
  44. 8.8.1 OSE Immunotherapeutics Company Information
  45. 8.8.2 OSE Immunotherapeutics Business Overview
  46. 8.8.3 OSE Immunotherapeutics Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio
  48. 8.8.5 OSE Immunotherapeutics Recent Developments
  49. 8.9 Novogene
  50. 8.9.1 Novogene Company Information
  51. 8.9.2 Novogene Business Overview
  52. 8.9.3 Novogene Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novogene Neoantigen Vaccine Product Portfolio
  54. 8.9.5 Novogene Recent Developments
  55. 8.10 Nouscom
  56. 8.10.1 Nouscom Company Information
  57. 8.10.2 Nouscom Business Overview
  58. 8.10.3 Nouscom Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nouscom Neoantigen Vaccine Product Portfolio
  60. 8.10.5 Nouscom Recent Developments
  61. 8.11 Moderna
  62. 8.11.1 Moderna Company Information
  63. 8.11.2 Moderna Business Overview
  64. 8.11.3 Moderna Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Moderna Neoantigen Vaccine Product Portfolio
  66. 8.11.5 Moderna Recent Developments
  67. 8.12 Medigene AG
  68. 8.12.1 Medigene AG Company Information
  69. 8.12.2 Medigene AG Business Overview
  70. 8.12.3 Medigene AG Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Medigene AG Neoantigen Vaccine Product Portfolio
  72. 8.12.5 Medigene AG Recent Developments
  73. 8.13 ISA Pharmaceuticals
  74. 8.13.1 ISA Pharmaceuticals Company Information
  75. 8.13.2 ISA Pharmaceuticals Business Overview
  76. 8.13.3 ISA Pharmaceuticals Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio
  78. 8.13.5 ISA Pharmaceuticals Recent Developments
  79. 8.14 Gritstone Bio
  80. 8.14.1 Gritstone Bio Company Information
  81. 8.14.2 Gritstone Bio Business Overview
  82. 8.14.3 Gritstone Bio Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Gritstone Bio Neoantigen Vaccine Product Portfolio
  84. 8.14.5 Gritstone Bio Recent Developments
  85. 8.15 Genocea Biosciences Inc
  86. 8.15.1 Genocea Biosciences Inc Company Information
  87. 8.15.2 Genocea Biosciences Inc Business Overview
  88. 8.15.3 Genocea Biosciences Inc Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio
  90. 8.15.5 Genocea Biosciences Inc Recent Developments
  91. 8.16 BrightPath Biotherapeutics
  92. 8.16.1 BrightPath Biotherapeutics Company Information
  93. 8.16.2 BrightPath Biotherapeutics Business Overview
  94. 8.16.3 BrightPath Biotherapeutics Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio
  96. 8.16.5 BrightPath Biotherapeutics Recent Developments
  97. 8.17 BioNTech
  98. 8.17.1 BioNTech Company Information
  99. 8.17.2 BioNTech Business Overview
  100. 8.17.3 BioNTech Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 BioNTech Neoantigen Vaccine Product Portfolio
  102. 8.17.5 BioNTech Recent Developments
  103. 8.18 Avidea Technologies
  104. 8.18.1 Avidea Technologies Company Information
  105. 8.18.2 Avidea Technologies Business Overview
  106. 8.18.3 Avidea Technologies Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Avidea Technologies Neoantigen Vaccine Product Portfolio
  108. 8.18.5 Avidea Technologies Recent Developments
  109. 8.19 Agenus Inc
  110. 8.19.1 Agenus Inc Company Information
  111. 8.19.2 Agenus Inc Business Overview
  112. 8.19.3 Agenus Inc Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Agenus Inc Neoantigen Vaccine Product Portfolio
  114. 8.19.5 Agenus Inc Recent Developments
  115. 8.20 Advaxis
  116. 8.20.1 Advaxis Company Information
  117. 8.20.2 Advaxis Business Overview
  118. 8.20.3 Advaxis Neoantigen Vaccine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Advaxis Neoantigen Vaccine Product Portfolio
  120. 8.20.5 Advaxis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst